Skip to main content
. 2024 May 30;16:1352681. doi: 10.3389/fnagi.2024.1352681

Figure 2.

Figure 2

Construction and validation of the prognostic signature. TCGA-Glioma: 631 glioma patients, 315 cases in the high-risk group and 316 cases in the low-risk group CGGA-693: 618 glioma patients, 365 cases in the high-risk group and 253 cases in the low-risk group CGGA-325: 306 glioma patients, 178 cases in the high-risk group and 128 cases in the low-risk group GSE16011: 249 glioma patients, 171 cases in the high-risk group and 78 cases in the low-risk group The significance of the survival curve was evaluated using the log-rank test. (A) Univariate Cox analysis identified 25 prognostic genes; (B,C) Coefficient profiles of the 19 prognostic PGFGs obtained through Lasso-Cox regression analysis. The Lasso regression model revealed the partial likelihood deviance of variables. Red dots represented the partial likelihood of deviance values, and gray lines represented the standard error (SE). The two vertical dotted lines on the left and right symbolized optimal values based on minimum criteria and 1 − SE criteria, respectively; (D) Meta-analysis demonstrated the heterogeneity and consistency of the signature across TCGA-Glioma, CGGA-693, CGGA-325, and GSE16011 datasets; (E–H) KM curves illustrated the differences in OS between the high-risk and low-risk groups in the TCGA-Glioma, CGGA-693, CGGA-325, and GSE16011 datasets; (I–L) Calibration curves denoted the accuracy and specificity of the signature. ROC curves displayed the 1-, 2-, and 3-year OS in the TCGA-Glioma (M), CGGA-693 (N), CGGA-325 (O), and GSE16011 (P) datasets.